Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars

Christine Berndt Previously Headed Biosimilar Development Programs At Sandoz

Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.

Wooden blocks leader selected chosen people put forward
Christine Berndt will be head of global development for specialty/biosimilar drugs at Stada • Source: Paradee Kietsirikul / Alamy Stock Photo

Christine Berndt, a former Sandoz executive who was a global program head for four biosimilar programs at the company, is to join Stada from June as head of global development for the German firm’s specialty and biosimilar division, with responsibility for “the development strategy and execution of Stada’s growing specialties and biosimilars portfolio.”

Berndt – who has most recently been working at MorphoSys as head of global program strategy, vice president, and member...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By 

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By 

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By 

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By 

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

More from Generics Bulletin

One Month Remains To Enter GGB Awards 2025

 
• By 

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By 

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

Biocon Biologics’ Yesafili Approved And Ready To Launch In Canada

 

Canada will welcome its first Eylea off-patent rival in July, as Biocon Biologics celebrates the commercialization of its 10th biosimilar worldwide.